Truist flips to Buy as EW options and analyst signals converge on earnings day

Edwards Lifesciences reports tonight. Three distinct data signals are pointing in the same direction this morning.

Truist Securities analyst Richard Newitter upgraded the stock to Buy from Hold this morning, lifting his price target 18.9% to $113. The stock last closed at $95.19, up 4.8% over the past week. The consensus sits at Buy with a mean target of $102.53 across 25 analysts, 19 of them bullish.

Options traders shift sharply toward calls

The put/call ratio has dropped to 0.86, sitting 2.2 standard deviations below its 20-day mean of 1.07. Three days ago, before this week's move, the ratio was near 1.10, in line with the prior month's range. The shift is abrupt. For the entire month of October the PCR held between 1.0 and 1.19. It broke below 0.90 only in the last two sessions.

That compares with a 52-week PCR low of 0.75. Today's reading is not at an extreme, but the speed of the move is.

Analyst momentum has been building

The Truist upgrade follows a string of constructive moves. Barclays initiated at Overweight with a $110 target in October. BTIG reiterated Buy at $110 in September. UBS assumed coverage at Buy in late July after the prior-quarter print. The analyst recommendation differential ranks in the 94th percentile against the broader market, the strongest single factor score in the snapshot.

The bull case rests on product-level volume: TAVR revenues growing 10.6% year-over-year and TMTT sales up 48.3% in the most recent quarter. Management has guided TMTT to $740 to $780 million for fiscal 2026. The bear case centres on margin compression. Adjusted operating margin came in at 23.7% last quarter against a consensus expectation of 25.9%, weighed by elevated SG&A costs.

Borrowing cost tick-up, but the lending market is loose

Cost to borrow has risen 63% over the past week to 0.60%. In absolute terms that is negligible. Borrow availability is at its maximum reading, with 571 million shares available against roughly 8.6 million sold short. Short interest at 1.5% of the free float has fallen roughly 12% over the past month. There is no pressure in the lending market, and the CTB move does not change that picture.

BlackRock added 6.2 million shares in the most recent reported quarter, lifting its stake to 10.2%. JP Morgan Asset Management added 1.3 million shares over the same period. Wikipedia attention for the stock is running at a z-score of 2.74 versus the company's own 90-day history, the highest retail-attention reading in the dataset.

Data summary

• Truist upgrades to Buy; raises target from $95 to $113
• PCR at 0.86, 2.2 standard deviations below the 20-day mean of 1.07
• Short interest at 1.5% of free float, down 12% over the past month
• Availability at maximum; cost to borrow 0.60%, up 63% on the week but low in absolute terms
• 19 Buy ratings, 6 Hold; mean consensus target $102.53
• Earnings due tonight after market close